Welcome to our dedicated page for Xtant Medical SEC filings (Ticker: XTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading an FDA-focused 10-K packed with clinical data or hunting down surgeon adoption metrics in an 8-K can feel overwhelming. Xtant Medical鈥檚 filings layer medical terminology atop SEC language, making it hard to spot what really moves revenue鈥攏ew orthobiologic launches, device recalls, or shifts in donor-tissue supply.
Stock Titan鈥檚 AI-powered summaries untangle that complexity. Whether you need the Xtant Medical quarterly earnings report 10-Q filing or the latest Xtant Medical insider trading Form 4 transactions, our platform explains each section in clear English, flags FDA risk statements, and highlights cash-flow drivers鈥攂efore you read a single footnote. AG真人官方-time alerts ensure Xtant Medical Form 4 insider transactions arrive the moment executives trade.
All filing types are here: the Xtant Medical annual report 10-K simplified for long-term strategy, 8-K material events explained for sudden developments like product launches, and the proxy statement covering Xtant Medical executive compensation. Need quick context? Ask natural questions like 鈥渦nderstanding Xtant Medical SEC documents with AI鈥� or 鈥淴tant Medical earnings report filing analysis鈥� and receive instant, reference-linked answers.
From tracking Xtant Medical executive stock transactions Form 4 to comparing biologic versus implant revenue across quarters, professionals save hours while making well-informed decisions. Complex filings made clear, updated the moment EDGAR publishes.
Xtant Medical Holdings (XTNT) has signed two definitive agreements dated 7 July 2025 to divest non-core spinal implant assets and its entire international hardware subsidiary to Companion Spine LLC.
- Coflex/CoFix Business (U.S.): Asset Purchase Agreement for $17.5 million subject to inventory adjustment. Companion has paid a non-refundable $2.5 million deposit; up to two additional deposits of the same size may be made if financing is delayed. At closing, XTNT will receive up to $6.8 million in cash plus an $8.2 million unsecured promissory note maturing 31 Dec 2025.
- Paradigm Spine GmbH (O.U.S. hardware): Equity sale for $1.7 million subject to cash, debt and working-capital adjustments.
- Inter-conditional closings: Each transaction must close simultaneously; both are targeted for Q3 2025 and are contingent on Buyer financing. Either party may terminate if not closed by 15 Sep 2025 (date extendable with extra deposits).
- Debt reduction: MidCap has granted limited consents allowing the sales, provided XTNT prepays $9.6 million of term-loan principal from proceeds.
The agreements include customary reps & warranties, a $250 k deductible and a $2 million indemnity cap. XTNT has added new risk-factor disclosures citing deal execution risk, potential business disruption, financing uncertainty and collectability of the $8.2 million note.
Strategic context: If completed, the divestitures convert lower-growth assets into liquidity, trim leverage and sharpen focus on XTNT鈥檚 core U.S. biologics portfolio. However, deal failure or Buyer default could materially harm cash flow and leave XTNT with stranded costs.
FAQ
What is the current stock price of Xtant Medical (XTNT)?
What is the market cap of Xtant Medical (XTNT)?
What core products does Xtant Medical develop?
Who are the primary customers of Xtant Medical?
How does Xtant Medical generate revenue?
What sets Xtant Medical apart from its competitors?
How does the company ensure product quality?
What is the significance of Xtant Medical's vertical integration strategy?
In what medical specialties are Xtant Medical's products primarily used?
How does Xtant Medical approach innovation?
